• Cancer cachexia: Rationale for the MENAC (Multimodal - Exercise, Nutrition and Anti-inflammatory medication for Cachexia) trial 

      Solheim, Tora Skeidsvoll; Laird, Barry J. A.; Balstad, Trude Rakel; Bye, Asta; Stene, Guro Birgitte; Baracos, Vickie; Strasser, Florian; Griffiths, Gareth; Maddocks, Matthew; Fallon, Marie; Kaasa, Stein; Fearon, Kenneth (BMJ Supportive & Palliative Care;Volume 8, Issue 3, Journal article; Peer reviewed, 2018-02-09)
      Cancer cachexia is a multifactorial syndrome characterized by an on-going loss of skeletal muscle mass that cannot be fully reversed by conventional nutritional support alone. Cachexia has a high prevalence in cancer ...
    • Physical function endpoints in cancer cachexia clinical trials: Systematic Review 1 of the cachexia endpoints series 

      McDonald, James; Sayers, Judith; Anker, Stefan D.; Arends, Jann; Balstad, Trude Rakel; Baracos, Vickie; Brown, Leo; Bye, Asta; Dajani, Olav; Dolan, Ross; Fallon, Marie T.; Fraser, Eilidh; Griel, Christine; Grzyb, Aleksandra; Hjermstad, Marianne Jensen; Jamal-Hanjani, Mariam; Jakobsen, Gunnhild; Kaasa, Stein; McMillan, Donald; Maddocks, Matthew; Philips, Iain; Ottestad, Inger; Reid, Kieran F.; Sousa, Mariana S.; Simpson, Melanie Rae; Vagnildhaug, Ola Magne; Skipworth, Richard J. E.; Solheim, Tora S; Laird, Barry J (Peer reviewed; Journal article, 2023)
      In cancer cachexia trials, measures of physical function are commonly used as endpoints. For drug trials to obtain regulatory approval, efficacy in physical function endpoints may be needed alongside other measures. However, ...